Valneva SE
VALN8.485USD
+0.125+1.50%
收盤 12/24, 13:00（美東）報價延遲15分鐘
1.38B總市值
虧損本益比TTM
關於 Valneva SE 公司
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE簡介
公司代碼VALN
公司名稱Valneva SE
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
員工數量- -
證券類型Depository Receipt
年結日Jun 28
公司地址6, Rue Alain Bombard
城市SAINT-HERBLAIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編44800
電話33228073710
網址https://valneva.com/
公司代碼VALN
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
Valneva SE公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Daniele Guyot-Caparros
Ms. Daniele Guyot-Caparros
Independent Director
Independent Director
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
地區USD
名稱
營收
佔比
United States
48.59M
28.66%
Canada
32.32M
19.06%
United Kingdom
19.49M
11.49%
Germany
18.37M
10.84%
Austria
15.90M
9.37%
其他
34.91M
20.58%
業務
地區
業務USD
名稱
營收
佔比
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
其他
93.97%
持股股東
持股股東
佔比
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
其他
93.97%
股東類型
持股股東
佔比
Venture Capital
2.73%
Private Equity
2.67%
Investment Advisor
0.47%
Research Firm
0.22%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.02%
其他
93.85%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
2023Q3
32
418.35K
0.60%
-285.66K
2023Q2
33
378.64K
0.55%
-602.57K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Novo Holdings A/S
2.38M
2.92%
+2.38M
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.46M
1.8%
+1.46M
--
Jun 30, 2025
General American Investors Company, Inc.
354.36K
0.44%
--
--
Jun 30, 2025
Wells Fargo Advisors
245.18K
0.3%
+1.96K
+0.81%
Jun 30, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
+113.00
+0.45%
Jun 30, 2025
Morgan Stanley & Co. International Plc
6.54K
0.01%
+2.82K
+75.62%
Jun 30, 2025
Citadel Advisors LLC
35.74K
0.04%
+8.52K
+31.30%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
1.48K
0%
--
--
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Valneva SE的前五大股東是誰？
Valneva SE的前五大股東如下：
Novo Holdings A/S持有股份：2.38M佔總股份比例：2.92%。
Frazier Life Sciences Management, L.P.持有股份：1.46M佔總股份比例：1.80%。
General American Investors Company, Inc.持有股份：354.36K佔總股份比例：0.44%。
Wells Fargo Advisors持有股份：245.18K佔總股份比例：0.30%。
Ironwood Investment Management, LLC持有股份：25.14K佔總股份比例：0.03%。
Novo Holdings A/S持有股份：2.38M佔總股份比例：2.92%。
Frazier Life Sciences Management, L.P.持有股份：1.46M佔總股份比例：1.80%。
General American Investors Company, Inc.持有股份：354.36K佔總股份比例：0.44%。
Wells Fargo Advisors持有股份：245.18K佔總股份比例：0.30%。
Ironwood Investment Management, LLC持有股份：25.14K佔總股份比例：0.03%。
Valneva SE的前三大股東類型是什麼？
Valneva SE 的前三大股東類型分別是：
Novo Holdings A/S
Frazier Life Sciences Management, L.P.
General American Investors Company, Inc.
Novo Holdings A/S
Frazier Life Sciences Management, L.P.
General American Investors Company, Inc.
有多少機構持有Valneva SE(VALN)的股份？
截至2025Q3，共有30家機構持有Valneva SE的股份，合計持有的股份價值約為4.53M，占公司總股份的5.58% 。與2025Q2相比，機構持股有所增加，增幅為4.77%。
哪個業務部門對Valneva SE的收入貢獻最大？
在FY2024，IXIARO業務部門對Valneva SE的收入貢獻最大，創收94.07M，占總收入的55.47% 。
